CR20250329A - Compuestos tricíclicos para el tratamiento del cáncer - Google Patents

Compuestos tricíclicos para el tratamiento del cáncer

Info

Publication number
CR20250329A
CR20250329A CR20250329A CR20250329A CR20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A CR 20250329 A CR20250329 A CR 20250329A
Authority
CR
Costa Rica
Prior art keywords
cancer
treatment
tricyclic compounds
sup
compounds
Prior art date
Application number
CR20250329A
Other languages
English (en)
Inventor
Junwei Xi
Wei Zhu
Lei Guo
Dan Zhao
Jianguo Chen
Haixia Liu
Hong Shen
Weixing Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20250329A publication Critical patent/CR20250329A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (Ib), (Ib), en donde R1 a R3 , M y L son como se describen en la presente, y su sal aceptable desde el punto de vista farmacéutico, enantiómeros o diastereómeros de estos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CR20250329A 2023-02-14 2024-02-08 Compuestos tricíclicos para el tratamiento del cáncer CR20250329A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023075911 2023-02-14
CN2023115515 2023-08-29
CN2024074420 2024-01-29
PCT/CN2024/076886 WO2024169914A1 (en) 2023-02-14 2024-02-08 Tricyclic compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
CR20250329A true CR20250329A (es) 2025-09-12

Family

ID=90363897

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250329A CR20250329A (es) 2023-02-14 2024-02-08 Compuestos tricíclicos para el tratamiento del cáncer

Country Status (13)

Country Link
US (2) US12247036B2 (es)
EP (1) EP4469164A1 (es)
JP (1) JP2026506637A (es)
KR (1) KR20250129811A (es)
CN (1) CN120813588A (es)
AU (1) AU2024220916A1 (es)
CL (1) CL2025002160A1 (es)
CO (1) CO2025010435A2 (es)
CR (1) CR20250329A (es)
IL (1) IL322109A (es)
MX (1) MX2025009239A (es)
PE (1) PE20252395A1 (es)
WO (1) WO2024169914A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025201453A1 (en) * 2024-03-28 2025-10-02 Beigene (Suzhou) Co., Ltd. Macrocyclic compounds as ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025252864A1 (en) * 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Macrocyclic compounds for the treatment of cancer
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026022119A1 (en) * 2024-07-24 2026-01-29 F. Hoffmann-La Roche Ag Ras inhibitors in combination therapy for use in treating cancers
WO2026027450A1 (en) * 2024-07-29 2026-02-05 F. Hoffmann-La Roche Ag Solid forms of ras inhibitor
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260078134A1 (en) * 2024-09-19 2026-03-19 Beone Medicines I Gmbh Macrocyclic Compounds as RAS Inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018091634A1 (en) 2016-11-18 2018-05-24 Neurovive Pharmaceutical Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
KR20210116479A (ko) 2018-12-21 2021-09-27 레볼루션 메디슨즈, 인크. 공동 결합에 참여하는 화합물 및 그의 용도
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2022005359A (es) * 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) * 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
IL307396A (en) 2021-04-02 2023-12-01 Massachusetts Gen Hospital Methods for inhibiting RAS
CN118453866A (zh) 2021-04-02 2024-08-09 综合医院公司 抑制ras的方法
TW202304452A (zh) 2021-04-09 2023-02-01 美商銳新醫藥公司 Ｓｏｓ１抑制劑與ｒａｓ抑制劑於治療癌症之用途
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
MX2023013912A (es) 2021-05-25 2024-02-12 Revolution Medicines Inc Metodos para inhibir ras.
WO2023015559A1 (en) 2021-08-13 2023-02-16 Nutshell Biotech (Shanghai) Co., Ltd. Macrocycle compounds as inhibitors of ras
AR126854A1 (es) 2021-08-27 2023-11-22 Hoffmann La Roche Compuestos macrocíclicos para el tratamiento de cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
CN118922423A (zh) 2022-01-10 2024-11-08 锐新医药公司 Ras抑制剂
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
TW202400607A (zh) 2022-04-25 2024-01-01 美商翰森生物有限責任公司 環狀化合物、製備方法及其醫藥用途
CN119301132A (zh) 2022-06-01 2025-01-10 豪夫迈·罗氏有限公司 用于治疗癌症的卤代吲哚大环化合物
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
JP2025522629A (ja) 2022-07-04 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のためのｋｒａｓの大環状阻害剤
CN119546613A (zh) 2022-07-08 2025-02-28 豪夫迈·罗氏有限公司 可用作kras抑制剂的大环化合物
AR129934A1 (es) 2022-07-20 2024-10-16 Hoffmann La Roche Compuestos macrocíclicos para el tratamiento de cáncer
EP4573095A1 (en) 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
EP4582426A4 (en) 2022-09-19 2025-12-24 Adlai Nortye Biopharma Co Ltd PAN-KRAS INHIBITOR COMPOUND
CN117720556A (zh) 2022-09-19 2024-03-19 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物及其制备方法和用途
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
CN120693161A (zh) 2022-10-12 2025-09-23 锐新医药公司 用于治疗癌症的包含第一ras抑制剂、第二ras抑制剂以及shp2抑制剂的组合物
EP4598921A1 (en) 2022-11-14 2025-08-13 Amgen Inc. Macrocyclic kras inhibitors and methods of use
WO2024104364A1 (zh) 2022-11-16 2024-05-23 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
LU505465B1 (en) 2022-11-16 2024-05-14 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
LU505464B1 (en) 2022-11-18 2024-05-13 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
CN117534684A (zh) 2022-11-29 2024-02-09 杭州阿诺生物医药科技有限公司 一种pan-KRAS抑制剂化合物
EP4649081A1 (en) 2023-01-13 2025-11-19 F. Hoffmann-La Roche AG Sulfonylvinyl compounds for the treatment of cancer
EP4653438A1 (en) 2023-01-19 2025-11-26 Genfleet Therapeutics (Shanghai) Inc. Macrocyclic compounds, preparation method therefor, and use thereof
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제

Also Published As

Publication number Publication date
US12247036B2 (en) 2025-03-11
WO2024169914A1 (en) 2024-08-22
US20250376482A1 (en) 2025-12-11
CO2025010435A2 (es) 2025-08-19
PE20252395A1 (es) 2025-10-10
EP4469164A1 (en) 2024-12-04
KR20250129811A (ko) 2025-08-29
CL2025002160A1 (es) 2025-08-22
US20240417410A1 (en) 2024-12-19
MX2025009239A (es) 2025-09-02
AU2024220916A1 (en) 2025-05-29
JP2026506637A (ja) 2026-02-25
IL322109A (en) 2025-09-01
CN120813588A (zh) 2025-10-17

Similar Documents

Publication Publication Date Title
CR20250329A (es) Compuestos tricíclicos para el tratamiento del cáncer
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
MX2024013838A (es) Compuestos y usos de estos
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CR20210513A (es) Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
WO2024006726A3 (en) Compounds as inhibitors of axl
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2025004959A (es) Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3)
MX2023015139A (es) Inhibidores de mutacion de her2.
CR20230382A (es) Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
MX2025005972A (es) Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3)
CR20220478A (es) Derivados de benzodiazepinas como pam de gaba a gamma 1
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2024002409A (es) Terapias contra el cancer.
MX2025002166A (es) Compuestos y metodos para modular her2
MX2024003645A (es) Derivados de piridinilacetamida como activadores de canales de sodio.
MX2025008428A (es) Derivados de piperidina como inhibidores de mettl3
MX2023007550A (es) Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k).
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria